151 related articles for article (PubMed ID: 18959484)
1. Is Bayh-Dole good for developing countries? Lessons from the US experience.
So AD; Sampat BN; Rai AK; Cook-Deegan R; Reichman JH; Weissman R; Kapczynski A
PLoS Biol; 2008 Oct; 6(10):e262. PubMed ID: 18959484
[TBL] [Abstract][Full Text] [Related]
2. Intellectual property. University licensing and the Bayh-Dole Act.
Thursby JG; Thursby MC
Science; 2003 Aug; 301(5636):1052. PubMed ID: 12933996
[No Abstract] [Full Text] [Related]
3. Bayh-Dole: if we knew then what we know now.
Boettiger S; Bennett AB
Nat Biotechnol; 2006 Mar; 24(3):320-3. PubMed ID: 16525405
[No Abstract] [Full Text] [Related]
4. Bayh-Dole: almost 25.
Kennedy D
Science; 2005 Mar; 307(5714):1375. PubMed ID: 15746390
[No Abstract] [Full Text] [Related]
5. March-in rights under the Bayh-Dole Act: the NIH's paper tiger?
O'Brien W
Seton Hall Law Rev; 2013 Nov; 43(4):1403-32. PubMed ID: 24308083
[No Abstract] [Full Text] [Related]
6. Patents, profits, and the American people--the Bayh-Dole Act of 1980.
Markel H
N Engl J Med; 2013 Aug; 369(9):794-6. PubMed ID: 23984726
[No Abstract] [Full Text] [Related]
7. Lessons from Bayh-Dole.
Sampat BN
Nature; 2010 Dec; 468(7325):755-6. PubMed ID: 21150971
[No Abstract] [Full Text] [Related]
8. Can we expect to achieve anything from Indian Bayh Dole?
Janodia MD; Sreedhar D; Ligade VS; Udupa N
Indian J Med Res; 2009 Oct; 130(4):487. PubMed ID: 19942757
[No Abstract] [Full Text] [Related]
9. Research interactions between industry and academia: a corporate perspective.
Citron P
Physiologist; 1996 Jun; 39(3):81, 90-2. PubMed ID: 16764116
[No Abstract] [Full Text] [Related]
10. The Bayh-Dole Act turns 30.
Loise V; Stevens AJ
Sci Transl Med; 2010 Oct; 2(52):52cm27. PubMed ID: 20926832
[TBL] [Abstract][Full Text] [Related]
11. Patents and innovation in cancer therapeutics: lessons from CellPro.
Bar-Shalom A; Cook-Deegan R
Milbank Q; 2002; 80(4):637-76, iii-iv. PubMed ID: 12532643
[TBL] [Abstract][Full Text] [Related]
12. Intellectual property and biotechnology: the U.S. internal experience--Part I.
Brody B
Kennedy Inst Ethics J; 2006 Mar; 16(1):1-37. PubMed ID: 16770885
[TBL] [Abstract][Full Text] [Related]
13. Surprise US election results may boost biotech.
Fox JL
Nat Biotechnol; 2002 Dec; 20(12):1176. PubMed ID: 12454655
[No Abstract] [Full Text] [Related]
14. Academic research: policies and practice.
Bertha SL
J Ethnopharmacol; 1996 Apr; 51(1-3):59-73. PubMed ID: 9213631
[TBL] [Abstract][Full Text] [Related]
15. Realizing Public Rights Through Government Patent Use.
Kapczynski A
J Law Med Ethics; 2021; 49(1):34-38. PubMed ID: 33966648
[TBL] [Abstract][Full Text] [Related]
16. Research and the Bayh-Dole Act.
Reczek PR
Science; 2004 Jan; 303(5654):40. PubMed ID: 14704412
[No Abstract] [Full Text] [Related]
17. Academic Medical Centers as Innovation Ecosystems: Evolution of Industry Partnership Models Beyond the Bayh-Dole Act.
Silva PJ; Ramos KS
Acad Med; 2018 Aug; 93(8):1135-1141. PubMed ID: 29668523
[TBL] [Abstract][Full Text] [Related]
18. Technology licensing: lessons from the US experience.
Sobolski GK; Barton JH; Emanuel EJ
JAMA; 2005 Dec; 294(24):3137-40. PubMed ID: 16380596
[No Abstract] [Full Text] [Related]
19. Columbia University's Axel patents: technology transfer and implications for the Bayh-Dole Act.
Colaianni A; Cook-Deegan R
Milbank Q; 2009 Sep; 87(3):683-715. PubMed ID: 19751286
[TBL] [Abstract][Full Text] [Related]
20. Intellectual property and biotechnology: the U.S. internal experience--Part II.
Brody B
Kennedy Inst Ethics J; 2006 Jun; 16(2):105-28. PubMed ID: 17036443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
